Jnj-67864238    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease2

96. Crohn disease    [ 2,209 clinical trials,   1,276 drugs,   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 2,209 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003335-37-DE
(EUCTR)
29/06/202027/11/2019A study to learn about the efficacy and safety of JNJ-67864238 in participants with Crohn's disease.A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn’s Disease: Intervention JNJ-67864238 - PRISM-SCARLET Treatment of moderately to severely active Crohn’s disease with JNJ-67864238.;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: JNJ-67864238
Product Code: JNJ-67864238
INN or Proposed INN: Not available
Other descriptive name: PTG-200
Janssen-Cilag International NVNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 2United States;Argentina;Poland;Russian Federation;Germany;Italy
2NCT04102111
(ClinicalTrials.gov)
September 23, 201923/9/2019A Study Evaluating Participants With Moderately to Severely Active Crohn's DiseaseA Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants With Moderately to Severely Active Crohn's DiseaseCrohn DiseaseDrug: JNJ-67864238;Drug: PlaceboJanssen Research & Development, LLCNULLRecruiting18 Years75 YearsAll90Phase 2United States;Argentina;France;Germany;Italy;Poland;Russian Federation;Ukraine